Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Predictive Value of Interim and End of Treatment PET/CT in Front-Line Treatment of Peripheral T-Cell Lymphoma

Nicolo Rampi, Belen Hervas Sanz, Carolina Esther Arevalo Leon, Angelo Castellani, Patricia Lopez Pereira, Elena Bechtold Javier, Ana C de Oliveira, Sara Pacella, Carmen Aguilera, Anna Valer, Eva Gonzalez Barca, Francesca Gaia Rossi, Carolina Martinez-Ramos, Ana Maria Sureda Balari, Montserrat Cortes-Romera, Eva Domingo Domenech

Blood (2024) 144 (Supplement 1): 6417.

https://doi.org/10.1182/blood-2024-210108

Published: 2024

Journal Articles

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Annalisa Paviglianiti, Marta Bellver Sanchis, Marta Peña, Inmaculada Peiro Martinez, Felipe Peña, Lidia Hurtado, Raquel Lopez Gil, Alberto Mussetti, Montserrat Arnan, Helena Pomares, Eva Gonzalez Barca, Patricia Lopez Pereira, Rocky Strollo, Paolo Pozzilli, Anna Sureda Balari

Blood (2024) 144 (Supplement 1): 7412.

https://doi.org/10.1182/blood-2024-198124

Published: 2024

Journal Articles

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 578.

https://doi.org/10.1182/blood-2024-200271

Published: 2024

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Blood (2024) 144 (Supplement 1): 4947.

https://doi.org/10.1182/blood-2024-202933

Published: 2024

Journal Articles

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Angel Serna, Angela Sanchez, Laia Lopez, Juan-Manuel Sancho, Eva Gonzalez Barca, Alberto Lopez-Garcia, Raul Cordoba, Adolfo Jesús Sáez Marín, Ana Isabel Jiminez Ubieto, Ainara Ferrero, Tomas García, Alba Cabirta, M Moraima Jimenez, Lucia Martin, Marta Julia, Sabela Bobillo, Ana Marin-Niebla, Francesc Bosch, Pau Abrisqueta

Blood (2022) 140 (Supplement 1): 9350–9352.

https://doi.org/10.1182/blood-2022-165996

Published: 2022

Journal Articles

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Blood (2022) 140 (Supplement 1): 9342–9344.

https://doi.org/10.1182/blood-2022-163165

Published: 2022

Journal Articles

Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies

Domingo Domenech Eva, Fina Climent, Eva Gonzalez Barca, Eugenia de Lama, Maria Martinez Iniesta, Monica Calaf, Clara Montane, Ana C Oliveira, Patricia Lopez, Gabriela Sanz-Linares, Esmeralda de la Banda, Laura Arregui, Villanueva Alberto, Anna Sureda, Lourdes Farre

Blood (2022) 140 (Supplement 1): 8829–8830.

https://doi.org/10.1182/blood-2022-164848

Published: 2022

Journal Articles

Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Domingo Domenech Eva, Marta Bellver, German Ferrer, Eva Gonzalez Barca, Itziar Carro, Ana C Oliveira, Patricia Lopez, Gabriela Sanz-Linares, Carmen Aguilera, Montserrat Alemany, Inmaculada Peiro, Anna Sureda, Roser Velasco

Blood (2022) 140 (Supplement 1): 9420–9421.

https://doi.org/10.1182/blood-2022-165345

Published: 2022

Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 224–227.

https://doi.org/10.1182/blood-2022-160338

Published: 2022

Journal Articles

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Blood (2022) 140 (Supplement 1): 9266–9268.

https://doi.org/10.1182/blood-2022-168552

Published: 2022

Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Jacob D. Soumerai, Masa Lasica, Stephen Opat, Chan Y. Cheah, Henry Chan, Emma Verner, Eva González Barca, Alessandra Tedeschi, James Hilger, Yiqian Fang, David Simpson, Constantine S. Tam

Blood (2022) 140 (Supplement 1): 9325–9327.

https://doi.org/10.1182/blood-2022-169664

Published: 2022

Journal Articles

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Paolo Strati, Dominik Chraniuk, Eva González-Barca, Michal Taszner, Rathi Pillai, Caly Chien, Shivani Nanda, Mark Rudinski, Vijayvel Jayaprakash, Marjo Hahka-Kemppinen, Marek Kania

Blood (2021) 138 (Supplement 1): 2432.

https://doi.org/10.1182/blood-2021-145641

Published: 2021

Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda

Blood (2021) 138 (Supplement 1): 68.

https://doi.org/10.1182/blood-2021-144544

Published: 2021

Journal Articles

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Domingo Domenech Eva, Juan-Manuel Sancho, Eva González-Barca, Nicholas Kelleher, Marta Rodriguez-Luaces, Jordina Rovira Sole, Silvia Verdesoto, Maite Encuentra, Damir Blazevic, Ana C Oliveira, Lourdes Escoda, Josep-Maria Ribera, Anna Sureda

Blood (2021) 138 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2021-149506

Published: 2021

Journal Articles

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Eva González-Barca, MD PhD, Johannes Duell, MD, Federica Cavallo, Juan-Manuel Sancho, MD PhD, Zsolt Nagy, MD PhD, Pau Abrisqueta, MD PhD, Carlos Panizo, MD PhD, Marinela Augustin, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD, Nagesh Kalakonda, MD, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-140294

Published: 2020

Journal Articles

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, Anna Marina Liberati, MD, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MDPhD, Gianluca Gaidano, Pau Abrisqueta, MD PhD, Marc André, MD, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-140314

Published: 2020

Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Blood (2019) 134 (Supplement_1): 5473.

https://doi.org/10.1182/blood-2019-126588

Published: 2019

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

NARROW

Predictive Value of Interim and End of Treatment PET/CT in Front-Line Treatment of Peripheral T-Cell Lymphoma

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies

Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30 + Peripheral T-Cell Lymphomas

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only